POSTED BY CARA SCHILLINGER ON 6/6/2013
ON 5/26/2013
MedPage Today published an article about an abstract on treating patients with IPF with reflux medicine that was presented at the 2013 ATS Conference.
POSTED BY ANDREA SMITH ON 5/8/2013
By Crystal Phend, Senior Staff Writer, MedPage Today
Published: May 06, 2013
Reviewed by F. Perry Wilson, MD, MSCE; Instructor of Medicine, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner
POSTED BY ANDREA SMITH ON 4/18/2013
A newly published study has discovered multiple genetic variations in patients with pulmonary fibrosis. These findings should help investigators better understand the disease and improve future efforts to treat the disease.
POSTED BY ANDREA SMITH ON 4/18/2013
A new study looking at the genomes of more than 1,500 patients with idiopathic pulmonary fibrosis (IPF) found multiple genetic associations with the disease. One gene variant was linked to an increased risk of death.
POSTED BY ANDREA SMITH ON 4/16/2013
Posted on the Wall Street Journal, U.S. online edition
April 16, 2013
CPF and PFF Joined Patients and Medical Professionals to Urge the Federally Mandated Program to Include Deadly Disease
POSTED BY CARA SCHILLINGER ON 4/11/2013
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0967]
Prescription Drug User Fee Act Patient-Focused Drug Development; Announcement of Disease Areas for Meetings Conducted in Fiscal Years 2013–2015
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of Availability.
POSTED BY CARA SCHILLINGER ON 3/28/2013
March 28, 2013
By Elizabeth Hunter, UW Health Sciences/UW Medicine
PFF PRESS RELEASE
POSTED BY CARA SCHILLINGER ON 3/27/2013
Contact:
Cara Schillinger
Associate Vice President, Marketing and Communications
Pulmonary Fibrosis Foundation
312.265.2184
cschillinger@pulmonaryfibrosis.org
PULMONARY FIBROSIS FOUNDATION ANNOUNCES OPEN REGISTRATION FOR INTERNATIONAL HEALTH CARE CONFERENCE ON PULMONARY FIBROSIS
POSTED BY CARA SCHILLINGER ON 3/26/2013
In draft guidance out today (Thursday 21 March), the National Institute for Health and Clinical Excellence (NICE) states its intention to recommend pirfenidone (also known as Esbriet and manufactured by InterMune) as a treatment option for certain people receiving NHS-funded care who have the chronic lung condition, idiopathic pulmonary fibrosis.
